Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved osimertinib (Tagrisso, AstraZeneca) for adult patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR (epidermal growth factor receptor) exon 19 deletions or exon 21 L858R mutations, as detected by an